Helius Medical Technologies Inc
Change company Symbol lookup
Select an option...
HSDT Helius Medical Technologies Inc
VTN Invesco Trust for New York Investment Grade Municipals
VVR Invesco Senior Income Trust
CLX Clorox Co
SNCY Sun Country Airlines Holdings Inc
NCZ Virtus Convertible & Income Fund II
XPEV Xpeng Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

Helius Medical Technologies, Inc. is a neurotech company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-implanted technologies targeted at reducing symptoms of neurological disease or trauma. The Company's product, Portable Neuromodulation Stimulator (PoNS), is a non-implanted medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS is used as a short-term treatment of gait deficit due to mild-to-moderate symptoms for multiple sclerosis (MS) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is also used as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy (PoNS Therapy).

Closing Price
$0.3056
Day's Change
-0.0064 (-2.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.3143
Day's Low
0.30
Volume
(Light)
Volume:
287,991

10-day average volume:
1,450,310
287,991

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

5:05 pm ET September 14, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:HSDT),(TSX:HSM), EQNX::TICKER_END Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced that, effective September 13, 2022, its compensation committee approved an equity award under Helius' 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

In connection with entering into employment with Helius, the individual, who was not a previous employee or director of Helius, received an option to purchase 10,000 shares of the Company's Class A common stock. The option award has an exercise price of $0.54 per share, the closing price of Helius' common stock on September 13, 2022, the date of the grant. The option has a ten-year term and vests over a period of four years, with 25% vesting on each of the first, second, third and fourth anniversary of September 1, 2022, provided the new hire's employment is continuing on each such date, and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the new hire's option agreement.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain's ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.

The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Therapy(TM)

The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis ("MS") and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming "early adopters" of PoNS therapy. For more information visit www.ponstherapy.com.

PoNS is also authorized for sale in Canada for two indications: (i) PoNS is authorized as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ("mmTBI") and is to be used in conjunction with physical therapy; and (ii) PoNS is authorized for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.

Investor Relations Contact

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

https://ml.globenewswire.com/media/f66facdd-4e51-49b4-b66a-d806d02134d5/small/helius-jpg.jpg

https://ml.globenewswire.com/media/f66facdd-4e51-49b4-b66a-d806d02134d5/small/helius-jpg.jpg

comtex tracking

COMTEX_414426734/2010/2022-09-14T17:05:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.